Immunotherapy against cancer translates as the activation of the immune system in the body to attack tumor cells, this type of treatments has gained much importance in recent decades as a viable strategy for the treatment of cancer. Immunotherapeutic treatments recently approved by the FDA have generated remission in patients with previously bleak results and have expanded the number of tools available to treat cancer. The nanoparticles, in different ways, whether polymeric, liposomal and metallic, naturally turn to highly irrigated tissues such as the spleen and lymphatic organs, which makes them good candidates for the administration of immunotherapeutic agents. Metal nanoparticle formulations, in particular, are useful because of their potential to enhance their ability to generate optical or laser-based therapeutic methods with magnetic fields.
When the particles are administered intravenously, the iron particle within a magnetic field, turns from one side to another, generating a constant heat. What produces a metabolic change in the cancer cell and generates its destruction in such a way that if it is possible to administer them directly in the tumor it is literally possible to generate the elimination of the tumor cells by means of heat.
Tumors need to grow rapidly and to achieve this, they stimulate the production of internal blood vessels. One of the side effects of this excessive stimulation in neovascularization is that the vessels are friable and lack effective lymphatic drainage, which helps the nanoparticles reach the parenchyma of the tumor.
Despite the important preclinical reports demonstrated by many research groups in the last twenty years, only a few metal nanoparticles have successfully entered clinical trials.
In our hospital we are working with NanoDynamics Inc. They as providers are one of the companies in the USA. They have FDA approval. Within the protocol registered in the national health institutes, there are several inclusion criteria among which candidate patients are selected to receive immunotherapy treatment.
• First, the patient must be between 25 and 75 years old
• The patient must have a neoplastic disease with solid tumor
• A progression prior to chemotherapy is important
• Two local doses should be administered if possible or 3 systemic doses
• The stimulation with the magnetic fields must be done twice a day
The protocol is carried out within the clinic and it is important to administer an important dose of antioxidant agents daily, the reason is to be able to cushion the components produced by the cell death of the tumor cells. Also control the food due to the amount of toxic components and pesticides contained in some types of food that can interfere with the distribution of magnetic particles.
Immune evasion is a characteristic of all types of cancer and contributes to tumor growth. In clinically healthy people, the body’s immune system recognizes abnormal cells and facilitates their destruction. Tumor cells evade such destruction by eliminating tumor antigens and immunosuppressing the attack function of T cells.
Cancer vaccines can induce the production and stimulation of T cells by being stimulated with tumor antigens, which often reside in the spleen, skin or lymphatic tissues. By promoting the production of dendritic cells, they interact with the CD8 + and Natural Killers T cells, initiating the maturation, expansion and migration processes to attack the sites of neoplasms.
If, together with immunostimulant therapy, nanoparticle therapy is administered, it is possible that a potentiation of the immune response is generated with the heat generated thereby generating the regression of the tumor masses.
- D. Hanahan, R.A. Weinberg, Cell 144 (2011) 646–674.
- R. Kim, M. Emi, K. Tanabe, Immunology 121 (2007) 1–14.
- A.B. Frey, Vaccine 33 (2015) 7393–7400.
- S. Farkona, E.P. Diamandis, I.M. Blasutig, BMC Med. 14 (2016) 73.
- J.J. Moon, B. Huang, D.J. Irvine, Adv. Mater. 24 (2012) 37
- B. Yu et al., Int. J. Nanomed. 12 (2017) 2553–2567.
- R. Mejias et al., Biomaterials 32 (2011) 2938–2952.
- S.K. Libutti et al., Clin. Cancer Res. 16 (2010) 6139–6149.
- M.M. Shenoi et al., Mol. Pharm. 10 (2013) 1683–1694.
- C. Ge et al., Chin. Clin. Oncol. 6 (2017) 18.
- M. Scholz, S. Yep, et al., Immunotargets Ther. 6 (2017) 11–16.
- Q. Zhou et al., ACS Nano 10 (2016) 2678–2692.